International, randomized, placebo-controlled, double-blind phase III study of motesanib plus carboplatin/paclitaxel in patients with advanced nonsquamous non-small-cell lung cancer: MONET1 - Scagliotti, G V; Vynnychenko, I; Park, K (J Clin Oncol, 2012)
, et al.